Early detection of pancreatic cancer using a blood test

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ExoLuminate study is a national registry aimed at improving early detection of pancreatic ductal adenocarcinoma (PDAC) in individuals at high risk or with clinical suspicion of the disease. It evaluates the effectiveness of the ExoVerita™ assay, a non-invasive blood test that isolates extracellular vesicles to identify biomarkers associated with early-stage PDAC. The study plans to enroll at least 1000 adults over three years, with follow-up data collection extending for two years. Participants will provide blood samples at specified intervals to assess the assay's performance compared to standard surveillance methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old.
* Meeting criteria for one of the study cohorts.
* Capable of giving informed consent.
* Able to provide a blood sample.

Exclusion Criteria:

* \< 18 years old.
* Pregnancy.
* Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
* Prior organ transplant or bone marrow transplant.
* History of fainting or other adverse effects when blood is drawn.
* Any condition that, in the opinion of the investigator, should preclude enrollment.

Where it's running

• Biological Dynamics
  San Diego, California, United States Recruiting

Study contacts

• Principal investigator: Harmeet Dhani, MD, M.Sc — Biological Dynamics
• Study coordinator: Harmeet Dhani, MD, M.Sc
• Email: exoluminate@biologicaldynamics.com
• Phone: 858-202-6150

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Combining surufatinib and camrelizumab with chemotherapy for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard options.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing · NCT05218889

• Understanding pancreatic cysts and their risks

  This study is trying to understand pancreatic cysts better to help doctors tell which ones are harmless and which ones might be dangerous, so patients can avoid unnecessary tests and surgeries.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT04473794

• Energy needs after pancreatic surgery: measuring metabolism to guide nutrition

  This study tests how much energy patients need after pancreatic surgery and compares direct measurements with common estimating methods to see if standard formulas are accurate.

  Recruiting Evangelismos Hospital · Athens, Attica · NCT07703813

• INSPIRE: Putting patient-reported info into multidisciplinary tumor boards

  This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama and 2 other locations · NCT07671937

• Indocyanine green–guided laparoscopic distal pancreatectomy vs standard approach for pancreatic body/tail lesions

  This trial tests whether using indocyanine green (ICG) fluorescence during laparoscopic distal pancreatectomy helps surgeons protect blood flow and structures, compared with the standard approach, in adults with pancreatic body or tail tumors.

  Recruiting Alexandria University · Alexandria · NCT07656571

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.